Current state of clinical trials in breast cancer brain metastases

J Fares, D Kanojia, A Cordero, A Rashidi… - Neuro-oncology …, 2019 - academic.oup.com
J Fares, D Kanojia, A Cordero, A Rashidi, J Miska, CW Schwartz, S Savchuk, AU Ahmed
Neuro-oncology practice, 2019academic.oup.com
Background Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology
for which more efficacious therapies are required. In this work, we explore clinical trials in
BCBM, and determine the shortcomings in the development of new BCBM therapies to shed
light on potential areas for enhancement. Methods On July 9, 2018, we searched
ClinicalTrials. gov for all interventional and therapeutic clinical trials involving BCBM, without
limiting for date or location. Information on trial characteristics, including phase, status, start …
Background
Breast cancer brain metastases (BCBM) are the final frontier in neuro-oncology for which more efficacious therapies are required. In this work, we explore clinical trials in BCBM, and determine the shortcomings in the development of new BCBM therapies to shed light on potential areas for enhancement.
Methods
On July 9, 2018, we searched ClinicalTrials.gov for all interventional and therapeutic clinical trials involving BCBM, without limiting for date or location. Information on trial characteristics, including phase, status, start and end dates, study design, primary endpoints, selection criteria, sample size, experimental interventions, results, and publications were collected and analyzed.
Results
Fifty-three trials fulfilled the selection criteria. Median trial duration across phases ranged between 3 and 6 years. More than half of the trials were conducted in the United States. Although 94% of the trials were in early phases (I-II), 20% of patients were in phase III trials. Two phase III trials were anteceded by phase II trials that were non-randomized; one reported positive results. Approximately one-third of the trials were completed, whereas 23% of trials were terminated early; mostly due to inadequate enrollment. Only 13% of all trials and 22% of completed trials had published results directly linked to their primary outcomes.
Conclusions
The low number of trials and accrual numbers, the lack of diversity, and the scarcity of published results represent the main troubles in clinical BCBM research. Optimization of BCBM trials is necessary to achieve effective therapies.
Oxford University Press